Board recommended final dividend of Re. 1 (50%) per equity share of the FV of Rs. 2 each for the FY 2024. the final dividend is subject to the approval of the members at he ensuing AGM which will be held within stipulated time.

pdf

Blue Jet Healthcare Ltd

25 May 2024

762.20

1.99%

Corp. Note

Blue Jet Healthcare Ltd - 544009 - Announcement under Regulation 30 (LODR)-Dividend Updates

BSE India

Board recommended final dividend of Re. 1 (50%) per equity share of FV of Rs. 2 each for FY 2024. The final dividend is subject to the approval of the members at the ensuring AGM which will be held within the stipulated timeline.

pdf

Blue Jet Healthcare Ltd

25 May 2024

762.20

1.99%

Result

Blue Jet Healthcare Ltd - 544009 - Board Meeting Outcome For Fourth Quarter And Financial Year …

BSE India

Board Meeting Outcome for Fourth Quarter and Financial Year ended 31st March 2024.

pdf

Blue Jet Healthcare Ltd

25 May 2024

762.20

1.99%

Board Meeting

Blue Jet Healthcare Ltd - 544009 - Board Meeting Outcome for Outcome Of Board Meeting

BSE India

Outcome of Board Meeting for the fourth quarter and financial year ended 31st March 2024.

pdf

Blue Jet Healthcare Ltd

22 May 2024

762.20

1.99%

Company Update

Blue Jet Healthcare Ltd - 544009 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - …

BSE India

Intimation of Analyst and investor call under Regulation 30 of the the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015.

pdf

Blue Jet Healthcare Ltd

17 May 2024, 02:48PM

762.20

1.99%

Board Meeting

Blue Jet Healthcare Ltd - 544009 - Board Meeting Intimation for Board Meeting Intimation As Per …

BSE India

Blue Jet Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/05/2024 ,inter alia, to consider and approve Pursuant to Regulation 29 and 33 of SEBI LODR Regulations 2015, we hereby inform you that the meeting of Board of directors of Bluejet Healthcare Limited is scheduled to be held on Saturday, 25th May, 2024 to inter alia consider the Following: 1. Approval of Audited Standalone Financial Results for the quarter and financial year ended 31st March 2024 along with audited report thereon. 2. To consider recommending final dividend on the equity shares of the Company for the financial year ended 31st March 2024, if any subject to the approval of the shareholders at the ensuring Annual General Meeting.